Evercore ISI Group Maintains Outperform on Summit Therapeutics, Lowers Price Target to $33

Benzinga · 2d ago
Evercore ISI Group analyst Cory Kasimov maintains Summit Therapeutics (NASDAQ:SMMT) with a Outperform and lowers the price target from $34 to $33.